Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 184

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 6
Chunk 184
---
 Compensation

The following table presents in the aggregate all
compensation we paid to all of our directors and senior management as a group for the year ended October 31, 2024. The table does not
include any amounts we paid to reimburse any of such persons for costs incurred in providing us with services during this period.

All amounts reported in the table below reflect
our cost, in United States dollars. Amounts paid in NIS are translated into United States dollars at the rate of NIS 3.7116= USD$1.00
for the year ended October 31, 2024 and NIS 3.6424 = USD$1.00 for the year ended October 31, 2023, based on the average representative
rate of exchange between the NIS and the Unites States dollars as reported by the Bank of Israel.

                                                                     For the year ended                                        
                                                                     October 31,                                               
                                                                     2024                                   2023               
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Compensation of key management personnel of the Company:                                                                     
  CEO management fees                                                $                         283,965      $         284,194  
  Share-based payment to CEO                                                                   163,552                125,695  
  CFO management fees                                                                          103,226                 90,278  
  Share-based payment to CFO                                                                    22,308                  2,824  
  Vice President of Business Development consulting fees                                        35,331                 35,594  
  Share-based payment to Vice President of Business Development                                    (17                 (3,711  
  Other related party transactions:                                                                                            
  Directors’ fees                                                                               85,397                 76,246  
  Share-based payment to Directors                                                             115,303                 11,038  
  Chairman management fees                                                                     157,206                106,015  
  Share-based payment to Chairman                                                              181,425                110,943  
  All directors and officers as a group                              $                       1,147,696      $         839,116  

For so long as we qualify as a foreign private
issuer, we will not be required to comply with the proxy rules applicable to U. S. domestic companies regarding disclosure of the compensation
of certain executive officers on an individual basis. Pursuant to applicable Canadian Securities Laws, we are required to disclose the
annual compensation of each of the following:

  the Company’s Chief Executive Officer (“